Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules



Status:Recruiting
Conditions:Endocrine, Endocrine
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:19 - Any
Updated:2/3/2019
Start Date:June 27, 2019
End Date:December 27, 2028

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Retrospective-Prospective Collection of Thyroid Specimens After FNA

This trial studies how well the diagnostic deoxyribonucleic acid (DNA) methylation signature
works in detecting thyroid cancer in patients with thyroid nodules. Using diagnostic testing,
such as the diagnostic DNA methylation signature, may be a less invasive way to check for
thyroid cancer.

PRIMARY OBJECTIVES:

I. To validate a novel epigenetic thyroid nodule diagnostic test, diagnostic DNA methylation
signature (DDMS) in a retrospective-prospective study with leftover of fine needle aspiration
biopsies.

OUTLINE:

Previously collected FNA aspiration specimen samples are analyzed via DDMS assay.
Participants undergo FNA aspiration for collection of tissue samples for analysis via DDMS
assay.

After completion of study, patients are followed up yearly for 5 years.

Inclusion Criteria:

- All patients undergoing FNA for thyroid nodule diagnosis.

- Any race and ethnicity are eligible for the study.

- Patient should have thyroid nodule(s) with indeterminate diagnosis after FNA (Bethesda
category of indeterminate FNA [III-V]).
We found this trial at
1
site
City of Hope Medical Center
Duarte, California 91010
Principal Investigator: Maria Hahn
Phone: 626-256-4673
?
mi
from
Duarte, CA
Click here to add this to my saved trials